BioCentury | Mar 8, 2010
Company News

Urigen board of directors update

...Pharmaceuticals Inc. (OTCBB:URGP), San Francisco, Calif. Business: Genitourinary Appointed: Edward Teitel, president and CEO of ThromboVision Inc....
BioCentury | Jan 4, 2010
Company News

ThromboVision, Emerging Healthcare Solutions Inc. deal

...Healthcare Solutions an option to invest in the biotech. If Emerging Healthcare exercises its option, ThromboVision...
...and cardiovascular drug Plavix clopidogrel to prevent heart attacks, stroke, blood clotting and stent occlusion. ThromboVision...
...Paris, France) and Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) (see BioCentury, Aug. 4, 2008). ThromboVision Inc....
BioCentury | Aug 4, 2008
Clinical News

ThromboGuide regulatory update

...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) market Plavix. ThromboVision Inc....
Items per page:
1 - 3 of 3
BioCentury | Mar 8, 2010
Company News

Urigen board of directors update

...Pharmaceuticals Inc. (OTCBB:URGP), San Francisco, Calif. Business: Genitourinary Appointed: Edward Teitel, president and CEO of ThromboVision Inc....
BioCentury | Jan 4, 2010
Company News

ThromboVision, Emerging Healthcare Solutions Inc. deal

...Healthcare Solutions an option to invest in the biotech. If Emerging Healthcare exercises its option, ThromboVision...
...and cardiovascular drug Plavix clopidogrel to prevent heart attacks, stroke, blood clotting and stent occlusion. ThromboVision...
...Paris, France) and Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) (see BioCentury, Aug. 4, 2008). ThromboVision Inc....
BioCentury | Aug 4, 2008
Clinical News

ThromboGuide regulatory update

...Squibb Co. (NYSE:BMY, New York, N.Y.) and sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) market Plavix. ThromboVision Inc....
Items per page:
1 - 3 of 3